NCT06794346View on ClinicalTrials.gov

Sexual Effects of Transdermal or Vaginal Testosterone

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 1, 2024

Study Completion Date

November 1, 2025

Conditions
Female Sexual DysfunctionPostmenopausal SymptomsTestosterone DeficiencyTestosterone Adverse Reaction
Interventions
DRUG

Transdermal testosterone

women will receive 300mcg of transdermal testosterone in cream daily for six months

DRUG

Vaginal testosterone gel

women will receive 300mcg of vaginal gel testosterone daily for six months

DEVICE

Placebo group

women will receive both vaginal gel and transdermal cream placebo for six months

Trial Locations (1)

04002021

Flavia Fairbanks, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER